Literature DB >> 12374276

Coordinate regulation of translation by the PI 3-kinase and mTOR pathways.

Kathleen A Martin1, John Blenis.   

Abstract

Control of translation initiation is an important means by which cells tightly regulate the critical processes of growth and proliferation. Multiple effector proteins contribute to translation initiation of specially modified mRNAs that modulate these processes. Coordinated regulation of these translational effectors by multiple signaling pathways allows the integration of information regarding mitogenic signals, energy levels, and nutrient sufficiency. The mTOR protein, in particular, serves as a sensor of all of these signals and is thought to thus serve as a crucial checkpoint control protein. Signals from the mTOR pathway converge with mitogenic inputs from the phosphoinositide (PI) 3-kinase pathway on translational effector proteins to coordinately control cellular growth, size, and cell proliferation. The translational effectors regulated by the PI 3-kinase and mTOR pathways and their roles in regulation of cellular growth will be the primary focus of this review.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374276     DOI: 10.1016/s0065-230x(02)86001-8

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  68 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 2.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

Review 3.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

4.  A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

5.  Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways.

Authors:  Chiara Gorrini; Fabrizio Loreni; Valentina Gandin; Leonardo A Sala; Nahum Sonenberg; Pier Carlo Marchisio; Stefano Biffo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-16       Impact factor: 11.205

Review 6.  Regulation and deregulation of mRNA translation during myeloid maturation.

Authors:  Arati Khanna-Gupta
Journal:  Exp Hematol       Date:  2010-11-18       Impact factor: 3.084

7.  Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase.

Authors:  Vincent A Bielinski; Marc C Mumby
Journal:  Exp Cell Res       Date:  2007-05-16       Impact factor: 3.905

8.  Inorganic polyphosphate stimulates mammalian TOR, a kinase involved in the proliferation of mammary cancer cells.

Authors:  Lihong Wang; Cresson D Fraley; Jesika Faridi; Arthur Kornberg; Richard A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-11       Impact factor: 11.205

9.  Expression, purification, and characterization of a structurally disordered and functional C-terminal autoinhibitory domain (AID) of the 70 kDa 40S ribosomal protein S6 kinase-1 (S6K1).

Authors:  Timothy J Ragan; Duncan B Ross; Malik M Keshwani; Thomas K Harris
Journal:  Protein Expr Purif       Date:  2007-10-01       Impact factor: 1.650

10.  PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Authors:  C A Crane; A Panner; J C Murray; S P Wilson; H Xu; L Chen; J P Simko; F M Waldman; R O Pieper; A T Parsa
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.